Wedbush Maintains Outperform on Denali Therapeutics, Raises Price Target to $31
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $30 to $31.
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $30 to $31.